文献速递疼痛医学

微创腰椎减压术治疗腰椎管狭窄伴神经源性跛行的2年安全性与疗效

Long-Term Safety and Efficacy of Minimally Invasive Lumbar Decompression Procedure for the Treatment of Lumbar Spinal Stenosis With Neurogenic Claudication: 2-Year Results of MiDAS ENCORE.
PubMed 文献 · Reg Anesth Pain Med · 2018-01-01

本研究为前瞻性多中心随机对照试验的2年随访报告,比较微创腰椎减压术(MILD)与硬膜外类固醇注射治疗腰椎管狭窄伴神经源性跛行的疗效。143例接受MILD,131例接受硬膜外类固醇注射,随机阶段随访6个月和1年,2年随访仅MILD组。结果显示MILD组所有结局指标从基线至2年随访均有临床意义和统计学显著改善,无严重器械/操作相关不良事件。

要点

  • MILD术后2年Oswestry功能障碍指数改善22.7分,疼痛数字评分改善3.6分。
  • 2年随访中无严重器械/操作相关不良事件,1.3%发生器械/操作相关不良事件。
  • MILD可作为特定中央型腰椎管狭窄伴神经源性跛行患者的一线治疗选择。

核心结论

  • MILD在2年随访中显示出良好的长期耐久性,无脊柱不稳证据。
  • 与棘突间撑开器、手术减压和脊柱融合等其他腰椎干预相比,MILD再手术率和脊柱骨折率更低、安全性更高。
  • 鉴于其微创性、稳健成功率和结局耐久性,MILD是特定中央型腰椎管狭窄伴神经源性跛行及黄韧带肥厚患者的一线治疗优选。

研究设计与样本

  • 前瞻性、多中心、随机对照临床研究,比较MILD与硬膜外类固醇注射的结局。
  • 143例接受MILD治疗,131例接受硬膜外类固醇注射治疗。
  • 随机阶段随访6个月和1年,2年随访仅针对MILD组受试者。
  • 采用Oswestry功能障碍指数、疼痛数字评分量表和苏黎世跛行问卷评估功能和疼痛。
  • 通过评估器械/操作相关不良事件发生率评价安全性。

主要发现

  • 所有结局指标从基线至6个月、1年和2年随访均显示有临床意义和统计学显著改善。
  • 2年时Oswestry功能障碍指数改善22.7分。
  • 2年时疼痛数字评分量表改善3.6分。
  • 2年时苏黎世跛行问卷症状严重程度和躯体功能领域分别改善1.0分和0.8分。
  • 无严重器械/操作相关不良事件,1.3%发生器械/操作相关不良事件。

临床怎么用

  • 对于黄韧带肥厚所致中央型腰椎管狭窄伴神经源性跛行的特定患者,可考虑将MILD作为一线治疗。
  • MILD术后2年随访显示功能与疼痛持续改善,且无脊柱不稳证据。

局限性

  • 2年随访仅纳入MILD组受试者,未与硬膜外类固醇注射组进行2年对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: This study evaluated the long-term durability of the minimally invasive lumbar decompression (MILD) procedure in terms of functional improvement and pain reduction for patients with lumbar spinal stenosis and neurogenic claudication due to hypertrophic ligamentum flavum. This is a report of 2-year follow-up for MILD study patients. METHODS: This prospective, multicenter, randomized controlled clinical study compared outcomes for 143 patients treated with MILD versus 131 treated with epidural steroid injections. Follow-up occurred at 6 months and at 1 year for the randomized phase and at 2 years for MILD subjects only. Oswestry Disability Index, Numeric Pain Rating Scale, and Zurich Claudication Questionnaire were used to evaluate function and pain. Safety was evaluated by assessing incidence of device-/procedure-related adverse events. RESULTS: All outcome measures demonstrated clinically meaningful and statistically significant improvement from baseline through 6-month, 1-year, and 2-year follow-ups. At 2 years, Oswestry Disability Index improved by 22.7 points, Numeric Pain Rating Scale improved by 3.6 points, and Zurich Claudication Questionnaire symptom severity and physical function domains improved by 1.0 and 0.8 points, respectively. There were no serious device-/procedure-related adverse events, and 1.3% experienced a device-/procedure-related adverse event. CONCLUSIONS: MILD showed excellent long-term durability, and there was no evidence of spinal instability through 2-year follow-up. Reoperation and spinal fracture rates are lower, and safety is higher for MILD versus other lumbar spine interventions, including interspinous spacers, surgical decompression, and spinal fusion. Given the minimally invasive nature of this procedure, its robust success rate, and durability of outcomes, MILD is an excellent choice for first-line therapy for select patients with central spinal stenosis suffering from neurogenic claudication symptoms with hypertrophic ligamentum flavum. CLINICAL TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov, identifier NCT02093520.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Staats PS, Chafin TB, Golovac S, et al. Long-Term Safety and Efficacy of Minimally Invasive Lumbar Decompression Procedure for the Treatment of Lumbar Spinal Stenosis With Neurogenic Claudication: 2-Year Results of MiDAS ENCORE. Reg Anesth Pain Med. 2018. PMID: 30199512. doi:10.1097/AAP.0000000000000868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。